Drug Trial Radar · NCT04176653
Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124
Last checked: Nov 19, 2026Latest source record: Apr 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Aug 20, 2019
Primary completion
Sep 30, 2021
Study completion Oct 14, 2021
Sponsor
- Lead sponsor
- Silence Therapeutics plcIndustry
- Sponsor type
- Industry
- First posted
- Nov 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to determine the safety and tolerability of SLN124 for the treatment of non-transfusion-dependent (NTD) β-thalassaemia and low risk myelodysplastic syndrome.
Conditions
- Non-transfusion-dependent Thalassemia
- Low Risk Myelodysplastic Syndrome
Interventions
SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as PlaceboDrug
IMP will be provided as a solution to be injected by qualified clinical staff in patient's abdomen, upper arms or front of the thighs.
Primary outcomes
What the sponsor says the trial is designed to measure.
- # of participants with all AEs as assessed by CTCAE V4.0 included injection site reaction, will be measured from baseline to post dose follow upTime frame: Up to two months
- 12 lead electrocardiogram parameters included PR, QTcF and QTcB will be measured from baseline to post dose follow upTime frame: Up to two months
- clinical chemistry, haematology, urinalysis, liver function tests (included ALT, AST, GGT) will be measured from baseline to post dose follow upTime frame: Up to two months
- height, weight, blood pressure, heart rate, respiration rate and temperature will be measured from baseline to post dose follow upTime frame: Up to two months
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
MHAT Dr. Nikola Vasiliev AD
Kyustendil, Bulgaria
UMHAT Dr. Georgi Stranski AD
Pleven, Bulgaria
Medical Center COMAC MEDICAL
Sofia, Bulgaria
UMHAT Sv. Ivan Rilski
Sofia, Bulgaria
Hammersmith Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.